These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33194475)

  • 1. Spontaneous Aortic Haematoma in a Patient Receiving Adjuvant Folinic Acid, 5-Fluorouracil, Irinotecan, and Oxaliplatin Chemotherapy Following Resection of a Pancreatic Adenocarcinoma.
    Dacie R; Woodhouse L; Mullan D; Lamarca A
    Cureus; 2020 Oct; 12(10):e10908. PubMed ID: 33194475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
    Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
    Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synchronous Primary Pancreatic Ductal Carcinoma and Colonic Adenocarcinoma Present in a Patient With History of Skin Squamous Cell Carcinoma.
    Cao C; Parikh P; Moezardalan K; Anantharaman A; Azarm A; Lai J
    Anticancer Res; 2020 Jul; 40(7):4029-4032. PubMed ID: 32620648
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathological complete response in pancreatic adenocarcinoma with FOLFIRINOX.
    Kao CT; Aziz M; Kasi A
    BMJ Case Rep; 2018 Sep; 2018():. PubMed ID: 30173133
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of recurrent small bowel adenocarcinoma by cytoreductive surgery and chemotherapy: a case report and review of the literature.
    Yamano T; Morii E; Arai I; Takada T; Aozasa K
    J Med Case Rep; 2010 Jul; 4():213. PubMed ID: 20637117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.
    Gornet JM; Azoulay D; Lévi F; Yovine A; Misset JL; Goldwasser F
    Anticancer Drugs; 2000 Apr; 11(4):263-8. PubMed ID: 10898541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report.
    Palmarocchi MC; Balzarotti Canger RC; Saletti P
    Oncol Lett; 2017 Jun; 13(6):4445-4452. PubMed ID: 28588713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
    Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bimonthly chemotherapy with oxaliplatin, irinotecan, infusional 5-fluorouracil/folinic acid in patients with metastatic colorectal cancer pretreated with irinotecan- or oxaliplatin-based chemotherapy.
    Nobili S; Checcacci D; Filippelli F; Del Buono S; Mazzocchi V; Mazzei T; Mini E
    J Chemother; 2008 Oct; 20(5):622-31. PubMed ID: 19028627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.
    Nywening TM; Wang-Gillam A; Sanford DE; Belt BA; Panni RZ; Cusworth BM; Toriola AT; Nieman RK; Worley LA; Yano M; Fowler KJ; Lockhart AC; Suresh R; Tan BR; Lim KH; Fields RC; Strasberg SM; Hawkins WG; DeNardo DG; Goedegebuure SP; Linehan DC
    Lancet Oncol; 2016 May; 17(5):651-62. PubMed ID: 27055731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Management of localized, locally advanced and metastatic pancreatic adenocarcinoma].
    Delpero JR; Turrini O; Raoul JL
    Rev Prat; 2015 Mar; 65(3):382-9. PubMed ID: 26016202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on liposomal irinotecan for metastatic pancreatic cancer: patient selection and perspectives.
    Woo W; Carey ET; Choi M
    Onco Targets Ther; 2019; 12():1455-1463. PubMed ID: 30863113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxaliplatin, irinotecan, and fluorouracil/folinic acid in advanced gastric cancer: a multicenter phase II trial of the Southern Italy Cooperative Oncology Group.
    Comella P; Lorusso V; Maiorino L; Casaretti R; Cannone M; Massidda B; Putzu C; Leo S; Roselli M; Mancarella S; Palmeri S; Greco E; Vessia G; Sandomenico C; Franco L
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):893-9. PubMed ID: 19189106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant chemotherapy for localised colon cancer. Fluorouracil + folinic acid for node-positive, non-metastatic disease.
    Prescrire Int; 2011 Feb; 20(113):46-9. PubMed ID: 21488594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized multicenter phase II study comparing a combination of fluorouracil and folinic acid and alternating irinotecan and oxaliplatin with oxaliplatin and irinotecan in fluorouracil-pretreated metastatic colorectal cancer patients.
    Bécouarn Y; Gamelin E; Coudert B; Négrier S; Pierga JY; Raoul JL; Provençal J; Rixe O; Krisch C; Germa C; Bekradda M; Mignard D; Mousseau M
    J Clin Oncol; 2001 Nov; 19(22):4195-201. PubMed ID: 11709562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral tegafur-uracil plus folinic acid versus intravenous 5-fluorouracil plus folinic acid as adjuvant chemotherapy of colon cancer.
    Kim DJ; Kim TI; Suh JH; Cho YS; Shin SK; Kang JK; Kim NK; Kim WH
    Yonsei Med J; 2003 Aug; 44(4):665-75. PubMed ID: 12950123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
    Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
    Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Severe Generalized Weakness, Paralysis, and Aphasia following Administration of Irinotecan and Oxaliplatin during FOLFIRINOX Chemotherapy.
    Chandar M; de Wilton Marsh R
    Case Rep Oncol; 2015; 8(1):138-41. PubMed ID: 25873880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy of metastatic colorectal cancer.
    Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.